Fenofibrate Targets Pparα-Cpt1C Axis To Reverse Aging By Regulating Lipid Metabolism And Mitochondrial Function
Aging is a complex process that affects everyone, and finding ways to slow or reverse its effects is a major goal in medical research. Recent findings suggest that an existing medication, fenofibrate, which is already approved for treating high cholesterol, may hold promise in this area. This drug appears to exert its anti-aging effects by targeting key cellular processes.
The research indicates that fenofibrate works by activating a protein called PPARα. Think of PPARα as a master switch that controls many genes involved in how our bodies handle fats and energy. When fenofibrate activates this switch, it leads to an increase in another important protein, CPT1C. This protein is crucial for the proper functioning of mitochondria, which are often called the “powerhouses” of our cells because they generate the energy our bodies need.
Essentially, by activating the PPARα-CPT1C pathway, fenofibrate helps to correct issues with how cells process fats (lipid metabolism) and improves the performance of mitochondria, both of which are known to decline with age. This leads to a reduction in age-related fat accumulation and better mitochondrial health in aged cells and animal models. This discovery is significant because it provides the first evidence that pharmacologically activating PPARα can directly influence the natural aging process by coordinating improvements in both fat metabolism and mitochondrial function.
Source: link to paper